Forbes -- New research has shown Novo Nordisk could clinch the diabetes drugs market with its successful liraglutide treatment in 2009. But investors in Amylin Pharmaceuticals and Eli Lilly, who jointly make a rival drug, shouldn't be too worried, as the duo might not be usurped for long.
